AI assistant
PMV Pharmaceuticals, Inc. — Director's Dealing 2024
Jan 11, 2024
34350_dirs_2024-01-11_400173f9-6f97-4371-b82d-0754458cb204.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2024-01-05
Reporting Person: Carulli Michael (Chief Financial Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 9066 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $4.22 | 2030-06-02 | Common Stock (24632) | Direct | |
| Employee Stock Option (right to buy) | $28.33 | 2031-05-12 | Common Stock (13605) | Direct | |
| Employee Stock Option (right to buy) | $16.29 | 2032-02-10 | Common Stock (27200) | Direct | |
| Employee Stock Option (right to buy) | $5.70 | 2033-05-12 | Common Stock (75000) | Direct |
Footnotes
F1: The shares are represented by restricted stock units which vest on September 9, 2024.
F2: An option to purchase 28,489 shares was granted on June 2, 2020 and was exercised in part prior to the date on which the reporting person became subject to Section 16. One-fourth of the shares subject to the option vested on May 26, 2021, and the remaining shares vest in 36 equal monthly installments beginning on June 26, 2021.
F3: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021.
F4: Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022.
F5: Shares subject to the option vest in 48 equal monthly installments beginning on June 12. 2023.